- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02140658
Affect of Health Education on Statins Medication Persistence and ClinicaL Prognosis of Ischemic Stroke Patients (HELP)
Affect of Multiple Health Education Interventions on Statins Medication Persistence and ClinicaL Prognosis of Ischemic Stroke Patients (HELP): a Prospective Cohort Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study is a prospective, multicenter, hospital-based study on secondary prevention for patients with ischemic cerebrovascular diseases between May 2014 and June 2015. Physicians from 24 hospitals in Beijing underwent a standard secondary prevention training of ischemic cerebrovascular diseases by professional training, instruction manuals, stratification management software. In order to improve the persistence of taking preventive secondary medicine, IS patients from these 24 hospitals received healthy education through manuals and Digital Video Disc about health education during hospitalization and acquired secondary preventive knowledge of ischemic cerebrovascular diseases through regular health education messages during 6 months after discharge. Patients with IS from other 6 hospitals were used as a control, and no such intervention was given to them.
Telephone follow-up was performed at 3 months, 6 months, and 1 year after the onset of cerebral infarction, during which the use of antiplatelet and statins drugs and recurrence of IS were recorded. Patients who took antiplatelet drugs or statins at three follow-ups were regarded as persistent antiplatelet drugs or statins taking within one year after the onset of the disease. The main prognostic indicator was the recurrence of IS and persistence of statins medication within 1 year, and the main purpose was to explore the impact of persistent statins use on IS recurrence.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Beijing, China, 100050
- Beijing Tian Tan Hospital, Capital Medical University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adult subjects (male or female ≥18 years);
- Acute ischemic stroke occured within 14 days of symptoms onset
- Blood low density lipoprotein (LDL) ≧100mg/dl(2.59mmol/L)
- Patients were prescribed statins at discharge
- Patients signed informed consent
- Patients have a cell phone and have the ability to receive and view messages
Exclusion Criteria:
- Non-cerebrovascular events or hemorrhagic stroke
- Patients have serious heart, liver, kidney dysfunction or coagulation disorders
- Patients have circumstances that may affect the follow-up such as disturbance of consciousness, severe depression or other mental disorders, aphasia
- Modified Rankin Scale score at discharge ≥3
- Patients with severe vision or vision field impairment which may affect patients to read message in cell phone
- Those who are participating in other clinical trials
- Those who can not guarantee with the completion of 6 month follow-up after enrollment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: multiple health education interventions
The first group will receive health education manuals and Digital Video Disc (DVD) during hospitalization and regular health education messages during 6 months after discharge.
|
|
Placebo Comparator: conventional health education
The second group will receive conventional health education during hospitalization except health education manuals, regular health education messages and Digital Video Disc (DVD)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of patients who continued taking statins drugs at three months after stroke onset.
Time Frame: 3 months after stroke onset
|
Statins Medication persistence at 3 months.
Patients who took statins at three months follow-up were regarded as persistent during three months.
|
3 months after stroke onset
|
Proportion of patients who continued taking statins drugs at six months after stroke onset.
Time Frame: 6 months after stroke onset
|
Statins Medication persistence at 6 months.Patients who took statins at six months follow-up were regarded as persistent at six months.
|
6 months after stroke onset
|
Proportion of patients who continued taking statins drugs at 12 months after stroke onset.
Time Frame: 12 months after stroke onset
|
Statins Medication persistence at 12 months.Patients who took statins at twelve months follow-up were regarded as persistent at twelve months.
|
12 months after stroke onset
|
Proportion of patients who continued taking statins drugs in 1 year after stroke onset.
Time Frame: 1 year after stroke onset
|
Statins Medication persistence in 1 year: Patients who took statins at 3, 6 and 12 months follow-up were regarded as persistent during one year after stroke onset.
|
1 year after stroke onset
|
Recurrence of ischemic stroke in three months after stroke onset
Time Frame: 3 months after stroke onset
|
Recurrence of ischemic stroke was defined as a new focal neurological deficit of vascular origin lasting >24 hours and without hemorrhage on computed tomography or MRI of the brain.
|
3 months after stroke onset
|
Recurrence of ischemic stroke in six months after stroke onset
Time Frame: 6 months after stroke onset
|
Recurrence of ischemic stroke was defined as a new focal neurological deficit of vascular origin lasting >24 hours and without hemorrhage on computed tomography or MRI of the brain.
|
6 months after stroke onset
|
Recurrence of ischemic stroke in 12 months after stroke onset
Time Frame: 12 months after stroke onset
|
Recurrence of ischemic stroke was defined as a new focal neurological deficit of vascular origin lasting >24 hours and without hemorrhage on computed tomography or MRI of the brain.
|
12 months after stroke onset
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of patients with 3-month poor clinical prognosis (including Death or Nonfatal myocardial infarction or Nonfatal hemorrhagic stroke or Severe disabilities) as a cluster and evaluated individually
Time Frame: 3 months after stroke onset
|
Death included Vascular death and non-vascular death; Severe disabilities was defined as modified Rankin Scale ≥4
|
3 months after stroke onset
|
Percentage of patients with 6-month poor clinical prognosis (including Death or Nonfatal myocardial infarction or Nonfatal hemorrhagic stroke or Severe disabilities) as a cluster and evaluated individually
Time Frame: 6 months after stroke onset
|
Death included Vascular death and non-vascular death; Severe disabilities was defined as modified Rankin Scale ≥4
|
6 months after stroke onset
|
Percentage of patients with 12-month poor clinical prognosis (including Death or Nonfatal myocardial infarction or Nonfatal hemorrhagic stroke or Severe disabilities) as a cluster and evaluated individually
Time Frame: 12 months after stroke onset
|
Death included Vascular death and non-vascular death; Severe disabilities was defined as modified Rankin Scale ≥4
|
12 months after stroke onset
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: yongjun wang, MD, Beijing Tian Tan Hospital, Capital Medical University, Beijing, China
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TTYY20140312
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ischemic Stroke
-
Nordsjaellands HospitalRigshospitalet, Denmark; Metropolitan University CollegeCompletedTransient Ischemic Attack | Stroke, Ischemic | Stroke HemorrhagicDenmark
-
University of CalgaryThe George Institute for Global Health, AustraliaNot yet recruitingAcute Ischemic Stroke AIS | Stroke, Acute, Stroke Ischemic | Stroke AcuteCanada, Australia
-
Second Affiliated Hospital, School of Medicine,...Shanghai Zhongshan Hospital; First Affiliated Hospital of Wenzhou Medical University and other collaboratorsRecruitingAcute Ischemic Stroke and Transient Ischemic AttacksChina
-
Medtronic Cardiac Rhythm and Heart FailureMedtronic Bakken Research CenterCompletedCryptogenic Symptomatic Transient Ischemic Attack | Cryptogenic Ischemic StrokeNetherlands, United States, France, Belgium, Germany, Sweden, Italy, Austria, Canada, Denmark, Finland, Greece, Slovakia, Spain
-
University Hospital, BrestCompletedStroke, Ischemic | Stroke HemorrhagicFrance
-
Umbria Bioengineering TechnologiesRecruitingStroke, Ischemic | Stroke HemorrhagicItaly
-
Sheffield Teaching Hospitals NHS Foundation TrustUnknownFatigue | Stroke, Ischemic | Stroke HemorrhagicUnited Kingdom
-
BayerRecruitingAcute Non-cardioembolic Ischemic Stroke | Prevention of Ischemic Stroke | High-risk Transient Ischemic AttackUnited States, Switzerland, Belgium, Sweden, Canada, Australia, Taiwan, Spain, Korea, Republic of, Latvia, Israel, Malaysia, Greece, Japan, Turkey, Netherlands, Romania, China, United Kingdom, Portugal, Italy, Brazil, France, Slovakia, ... and more
-
University of AlbertaCompletedTransient Ischemic Attack | Minor Ischemic StrokeCanada
-
Stephanie HarrisonActive, not recruitingTransient Ischemic Attack | Stroke, IschemicUnited Kingdom
Clinical Trials on multiple health education interventions
-
yongjun wangMinistry of Science and Technology of the People´s Republic of ChinaCompletedIschemic Stroke | Medication PersistenceChina
-
University of BahrainCompletedSelf-Efficacy | Self-CareBahrain
-
International Food Policy Research InstituteFHI 360; Addis Continental Institute of Public HealthCompletedMaternal Dietary Diversity | Iron-Folic Acid Supplementation | Early Initiation of BreastfeedingUnited States
-
International Food Policy Research InstituteFHI 360; AFRICSantéCompletedMaternal Dietary Diversity | Iron-Folic Acid Supplementation | Early Initiation of BreastfeedingUnited States
-
VA Office of Research and DevelopmentRecruitingPhysical Deconditioning | MultimorbidityUnited States
-
National Taipei University of Nursing and Health...Cheng-Hsin General HospitalRecruitingHealth Literacy | Endocrine Disrupting ChemicalsTaiwan
-
Queen Elizabeth Hospital, Hong KongUnknownParkinson DiseaseHong Kong
-
Sequenom, Inc.RecruitingCancer | Infectious Disease | Pregnancy RelatedUnited States
-
University of TorontoAssociation for Social Development, Pakistan; Canadian Institutes of Health...RecruitingCOVID-19 | Noncommunicable DiseasesPakistan
-
University of Alabama at BirminghamNational Cancer Institute (NCI); University of TennesseeActive, not recruitingKidney Cancer | Breast Cancer | Multiple Myeloma | Colorectal Cancer | Prostate Cancer | Non-Hodgkin Lymphoma | Endometrial Cancer | Thyroid Cancer | Ovary CancerUnited States